aVaxziPen

Executive Summary

aVaxziPen is a UK-based biotech company pioneering a needle-free, solid-dose vaccine delivery platform. Its core technology produces thermally stable, highly immunogenic vaccine formulations that are smaller than a grain of rice and dissolve rapidly upon administration. This approach eliminates the need for cold chain storage and reduces antigen dose requirements, potentially revolutionizing vaccine logistics and accessibility. Founded in 2017 and headquartered in Oxford, the company operates at the intersection of drug delivery and vaccines, addressing key challenges in global immunization, particularly for resource-limited settings. The platform's ability to simplify vaccine distribution and administration positions it strongly in the growing market for needle-free delivery systems. With increasing demand for thermostable vaccines and dose-sparing technologies, aVaxziPen's solution could appeal to partners in both public health and commercial vaccine development. While the company remains in a relatively early stage, its technology has the potential to disrupt traditional vaccine manufacturing and supply chains.

Upcoming Catalysts (preview)

• TBDSeries A Funding Round70% success
• TBDIndustry Partnership for Co-Development50% success
• TBDPreclinical Proof-of-Concept Data Publication80% success